A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.

Trial Details

NCT ID
NCT07049055
Phase
PHASE1 / PHASE2
Sponsor
Engeneic Pty Limited
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • E-EDV-D682
  • EDV-GC
  • Gemcitabine
  • Nab paclitaxel.
Locations (sample)
  • El Segundo, California, United States|33.91918,-118.41647
  • Summit, New Jersey, United States|40.71562,-74.36468
  • New York, New York, United States|40.71427,-74.00597
  • Maumee, Ohio, United States|41.56283,-83.65382

Key Eligibility Criteria

  • Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is requ…
  • Male or Female greater than or equal to 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.
  • Life expectancy ≥ 3 months in the opinion of the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →